A citation-based method for searching scientific literature

Peipei Yang, Ying Qu, Mengyao Wang, Bingyang Chu, Wen Chen, Yuhuan Zheng, Ting Niu, Zhiyong Qian. MedComm (2020) 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art.
Mengyao Wang, Ying Qu, Danrong Hu, Ting Niu, Zhiyong Qian. J Biomed Nanotechnol 2021
1
100

Nanotherapeutics for multiple myeloma.
Alexander Zheleznyak, Monica Shokeen, Samuel Achilefu. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2018
6
100

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.
S V Rajkumar, V Gupta, R Fonseca, A Dispenzieri, W I Gonsalves, D Larson, R P Ketterling, J A Lust, R A Kyle, S K Kumar. Leukemia 2013
134
100

Multiple myeloma.
Niels W C J van de Donk, Charlotte Pawlyn, Kwee L Yong. Lancet 2021
90
100

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Jacob P Laubach, Fredrik Schjesvold, Mário Mariz, Meletios A Dimopoulos, Ewa Lech-Maranda, Ivan Spicka, Vania T M Hungria, Tatiana Shelekhova, Andre Abdo, Lutz Jacobasch,[...]. Lancet Oncol 2021
26
100


The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
Anne Catherine Sprynski, Dirk Hose, Laurent Caillot, Thierry Réme, John D Shaughnessy, Bart Barlogie, Anja Seckinger, Jérôme Moreaux, Michael Hundemer, Michel Jourdan,[...]. Blood 2009
113
100

What is nanomedicine?
Robert A Freitas. Nanomedicine 2005
159
100

CD38 as an immunotherapeutic target in multiple myeloma.
Francesca Bonello, Mattia D'Agostino, Maria Moscvin, Chiara Cerrato, Mario Boccadoro, Francesca Gay. Expert Opin Biol Ther 2018
19
100

Multiple myeloma.
Antonio Palumbo, Kenneth Anderson. N Engl J Med 2011
100

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Brian G M Durie, Antje Hoering, Rachael Sexton, Muneer H Abidi, Joshua Epstein, S Vincent Rajkumar, Angela Dispenzieri, Stephen P Kahanic, Mohan C Thakuri, Frederic J Reu,[...]. Blood Cancer J 2020
75
100

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Yu-Tzu Tai, Kenneth C Anderson. Expert Opin Biol Ther 2019
41
100

Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
Jonathan D Ashley, Jared F Stefanick, Valerie A Schroeder, Mark A Suckow, Tanyel Kiziltepe, Basar Bilgicer. J Med Chem 2014
49
100

Research Progress of Thermosensitive Hydrogel in Tumor Therapeutic.
Nian Ma, Zhihui Yan. Nanoscale Res Lett 2021
2
100

Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy.
Kinan Alhallak, Jennifer Sun, Katherine Wasden, Nicole Guenthner, Julie O'Neal, Barbara Muz, Justin King, Daniel Kohnen, Ravi Vij, Samuel Achilefu,[...]. Leukemia 2021
10
100

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Brian A Walker, Eileen M Boyle, Christopher P Wardell, Alex Murison, Dil B Begum, Nasrin M Dahir, Paula Z Proszek, David C Johnson, Martin F Kaiser, Lorenzo Melchor,[...]. J Clin Oncol 2015
345
100

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos,[...]. N Engl J Med 2016
913
100

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Christine Galustian, Brendan Meyer, Marie-Christine Labarthe, Keith Dredge, Deborah Klaschka, Jake Henry, Stephen Todryk, Roger Chen, George Muller, David Stirling,[...]. Cancer Immunol Immunother 2009
299
100

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Cinzia Federico, Kinan Alhallak, Jennifer Sun, Kathleen Duncan, Feda Azab, Gail P Sudlow, Pilar de la Puente, Barbara Muz, Vaishali Kapoor, Luna Zhang,[...]. Nat Commun 2020
22
100

Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations.
Sonam Chaudhary, Avinash Gothwal, Iliyas Khan, Shubham Srivastava, Ruchi Malik, Umesh Gupta. Mater Sci Eng C Mater Biol Appl 2017
4
100

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim Doronin,[...]. Lancet 2020
95
100

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Brian G M Durie, Antje Hoering, Muneer H Abidi, S Vincent Rajkumar, Joshua Epstein, Stephen P Kahanic, Mohan Thakuri, Frederic Reu, Christopher M Reynolds, Rachael Sexton,[...]. Lancet 2017
488
100

Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.
Guido Ghilardi, Thomas Pabst, Barbara Jeker, Rouven Müller, Anne Cairoli, Antonia M S Müller, Mario Bargetzi, Felicitas Hitz, Helen Baldomero, Dominik Heim,[...]. Bone Marrow Transplant 2019
10
100



Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, A Keith Stewart, Parameswaran Hari, Myo Htut, Alexander Lesokhin,[...]. Lancet 2021
143
100

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Nizar J Bahlis, Meletios A Dimopoulos, Darrell J White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau,[...]. Leukemia 2020
88
100

Potential Therapeutic Roles of Exosomes in Multiple Myeloma: A Systematic Review.
Mengzhen Li, Bing Xia, Yi Wang, M James You, Yizhuo Zhang. J Cancer 2019
16
100

Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.
Jonathan D Ashley, Jared F Stefanick, Valerie A Schroeder, Mark A Suckow, Nathan J Alves, Rikio Suzuki, Shohei Kikuchi, Teru Hideshima, Kenneth C Anderson, Tanyel Kiziltepe,[...]. J Control Release 2014
38
100

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Dan T Vogl, Noopur Raje, Sundar Jagannath, Paul Richardson, Parameswaran Hari, Robert Orlowski, Jeffrey G Supko, David Tamang, Min Yang, Simon S Jones,[...]. Clin Cancer Res 2017
142
100

The genetic architecture of multiple myeloma.
Gareth J Morgan, Brian A Walker, Faith E Davies. Nat Rev Cancer 2012
575
100

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balaji Balasa, Rui Yun, Nicole A Belmar, Melvin Fox, Debra T Chao, Michael D Robbins, Gary C Starling, Audie G Rice. Cancer Immunol Immunother 2015
104
100

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
Barbara Savoldo, Carlos Almeida Ramos, Enli Liu, Martha P Mims, Michael J Keating, George Carrum, Rammurti T Kamble, Catherine M Bollard, Adrian P Gee, Zhuyong Mei,[...]. J Clin Invest 2011
704
100

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Sagar Lonial, Brendan M Weiss, Saad Z Usmani, Seema Singhal, Ajai Chari, Nizar J Bahlis, Andrew Belch, Amrita Krishnan, Robert A Vescio, Maria Victoria Mateos,[...]. Lancet 2016
564
100

Kinase domain activation through gene rearrangement in multiple myeloma.
Gareth J Morgan, Jie He, Ruslana Tytarenko, Purvi Patel, Owen W Stephens, Shan Zhong, Shayu Deshpande, Michael Bauer, Niels Weinhold, Carolina Schinke,[...]. Leukemia 2018
19
100

Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Maya Bar-Zeev, Yoav D Livney, Yehuda G Assaraf. Drug Resist Updat 2017
148
100

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets.
Jessica Burroughs Garcìa, Rosa Alba Eufemiese, Paola Storti, Gabriella Sammarelli, Luisa Craviotto, Giannalisa Todaro, Denise Toscani, Valentina Marchica, Nicola Giuliani. Cells 2021
3
100

PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
Catia Morelli, Pamela Maris, Diego Sisci, Enrico Perrotta, Elvira Brunelli, Ida Perrotta, Maria Luisa Panno, Antonio Tagarelli, Carlo Versace, Maria Francesca Casula,[...]. Nanoscale 2011
59
100

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
Pilar de la Puente, Micah J Luderer, Cinzia Federico, Abbey Jin, Rebecca C Gilson, Christopher Egbulefu, Kinan Alhallak, Shruti Shah, Barbara Muz, Jennifer Sun,[...]. J Control Release 2018
34
100

Immune Cell Membrane-Coated Biomimetic Nanoparticles for Targeted Cancer Therapy.
Fatemeh Oroojalian, Mohammad Beygi, Behzad Baradaran, Ahad Mokhtarzadeh, Mohammad-Ali Shahbazi. Small 2021
44
100

Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment.
Koichiro Hayashi, Michihiro Nakamura, Wataru Sakamoto, Toshinobu Yogo, Hirokazu Miki, Shuji Ozaki, Masahiro Abe, Toshio Matsumoto, Kazunori Ishimura. Theranostics 2013
158
100

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
Robert Z Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hajek, Andrew Spencer, Tadeusz Robak, Anna Dmoszynska, Noemi Horvath, Ivan Spicka,[...]. Cancer 2016
28
100

Injectable Coacervate Hydrogel for Delivery of Anticancer Drug-Loaded Nanoparticles in vivo.
Ashlynn L Z Lee, Zhi Xiang Voo, Willy Chin, Robert J Ono, Chuan Yang, Shujun Gao, James L Hedrick, Yi Yan Yang. ACS Appl Mater Interfaces 2018
34
100

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Saad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, Hareth Nahi, Jesus F San-Miguel, Albert Oriol, Laura Rosinol, Ajai Chari, Manisha Bhutani, Lionel Karlin,[...]. Lancet 2021
39
100

Ixazomib: First Global Approval.
Matt Shirley. Drugs 2016
77
100

The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression.
Almudena García-Ortiz, Yaiza Rodríguez-García, Jessica Encinas, Elena Maroto-Martín, Eva Castellano, Joaquín Teixidó, Joaquín Martínez-López. Cancers (Basel) 2021
30
100

A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways.
Bryan Q Spring, R Bryan Sears, Lei Zak Zheng, Zhiming Mai, Reika Watanabe, Margaret E Sherwood, David A Schoenfeld, Brian W Pogue, Stephen P Pereira, Elizabeth Villa,[...]. Nat Nanotechnol 2016
147
100

Signaling Pathway Mediating Myeloma Cell Growth and Survival.
Teru Hideshima, Kenneth C Anderson. Cancers (Basel) 2021
14
100

Daratumumab Immunopolymersome-Enabled Safe and CD38-Targeted Chemotherapy and Depletion of Multiple Myeloma.
Na Yu, Yifan Zhang, Jiaying Li, Wenxing Gu, Shujing Yue, Bin Li, Fenghua Meng, Huanli Sun, Rainer Haag, Jiandong Yuan,[...]. Adv Mater 2021
5
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.